Ipidacrine

Jump to: navigation, search
Ipidacrine
Ipidacrine.png
Clinical data
Trade namesNeiromidin
SynonymsAmiridine; NIK-247
ATC code
Legal status
Legal status
  • US: Unscheduled
Identifiers
PubChem CID
ChemSpider
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC12H16N2
Molar mass188.27 g/mol
3D model (JSmol)


WikiDoc Resources for Ipidacrine

Articles

Most recent articles on Ipidacrine

Most cited articles on Ipidacrine

Review articles on Ipidacrine

Articles on Ipidacrine in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Ipidacrine

Images of Ipidacrine

Photos of Ipidacrine

Podcasts & MP3s on Ipidacrine

Videos on Ipidacrine

Evidence Based Medicine

Cochrane Collaboration on Ipidacrine

Bandolier on Ipidacrine

TRIP on Ipidacrine

Clinical Trials

Ongoing Trials on Ipidacrine at Clinical Trials.gov

Trial results on Ipidacrine

Clinical Trials on Ipidacrine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Ipidacrine

NICE Guidance on Ipidacrine

NHS PRODIGY Guidance

FDA on Ipidacrine

CDC on Ipidacrine

Books

Books on Ipidacrine

News

Ipidacrine in the news

Be alerted to news on Ipidacrine

News trends on Ipidacrine

Commentary

Blogs on Ipidacrine

Definitions

Definitions of Ipidacrine

Patient Resources / Community

Patient resources on Ipidacrine

Discussion groups on Ipidacrine

Patient Handouts on Ipidacrine

Directions to Hospitals Treating Ipidacrine

Risk calculators and risk factors for Ipidacrine

Healthcare Provider Resources

Symptoms of Ipidacrine

Causes & Risk Factors for Ipidacrine

Diagnostic studies for Ipidacrine

Treatment of Ipidacrine

Continuing Medical Education (CME)

CME Programs on Ipidacrine

International

Ipidacrine en Espanol

Ipidacrine en Francais

Business

Ipidacrine in the Marketplace

Patents on Ipidacrine

Experimental / Informatics

List of terms related to Ipidacrine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Ipidacrine (Neiromidin) is a novel substance synthesized by the National Research Center for Biologically Active Compounds in the Russian Federation. This compound contains the structure of 4-aminopyridine and is structurally very similar to tacrine.[1]

Ipidacrine is a reversible acetylcholinesterase inhibitor used in memory disorders of different origins.[2][3][4]

Ipidacrine directly stimulates impulse transmission in the CNS and neuromuscular synapses by blocking membrane potassium channels. Neiromidin enhances not only choline, but also adrenaline, serotonin, histamine and oxytocin effects on smooth muscle.[5]

References

  1. Kojima, Jun; Onodera, Kenji; Ozeki, Mitsuo; Nakayama, Kunio (1998). "Ipidacrine (NIK-247): A Review of Multiple Mechanisms as an Antidementia Agent". CNS Drug Reviews. 4 (3): 247. doi:10.1111/j.1527-3458.1998.tb00067.x.
  2. Damulin, IV; Stepkina, DA; Lokshina, AB (2011). "Neuromidin in mixed vascular and Alzheimer's dementia". Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov \i] Vserossiiskoe obshchestvo psikhiatrov. 111 (2): 40–3. PMID 21350422.
  3. Pustokhanova, LV; Morozova, EM (2011). "Cognitive disorders in the early rehabilitation period of ischemic stroke and possibilities of their treatment with neuromidin". Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov \i] Vserossiiskoe obshchestvo psikhiatrov. 111 (4 Pt 2): 23–7. PMID 23120773.
  4. Onodera, K; Kojima, J; Wachi, M (1998). "Ipidacrine (NIK-247), a novel antidementia, rapidly enters the brain and improves scopolamine-induced amnesia in rats during the Morris water maze task". Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology. 18 (2): 33–7. PMID 9656230.
  5. Neiromidin Product Information



Linked-in.jpg